Form 4: Ultragenyx CFO Howard Horn Receives Equity Grant

Ultragenyx Pharmaceutical CFO Howard Horn was granted 34,674 restricted stock units and 59,952 stock options as part of the company's 2023 incentive plan.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., received an equity compensation package on April 16, 2026.
• The grant includes 34,674 Restricted Stock Units (RSUs) which vest over four years at a rate of 25% per year.
• The grant also includes 59,952 stock options with an exercise price of $24.52 per share.
• The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting monthly over the following three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value creation.
• The multi-year vesting schedule encourages executive retention.

Negatives

• The issuance of new equity results in potential dilution for existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these grants.
• Vesting conditions are subject to the executive's continued employment with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of executive compensation.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure alignment with long-term R&D and commercialization milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for U.S. publicly traded biotech companies.
• The use of both RSUs and stock options is a common compensation structure for executive retention in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of 1/4th of the RSUs on April 16, 2027.
• Vesting of 1/4th of the stock options on April 16, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Executive Compensation, CFO, Equity Grant